Needham Reiterates Buy on Cytokinetics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Cytokinetics (NASDAQ:CYTK) and maintained a price target of $60.
October 20, 2023 | 8:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Cytokinetics, maintaining a price target of $60.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $60 price target indicates a positive outlook for Cytokinetics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100